INVA
HEALTHCAREInnoviva Inc
$22.52-0.13 (-0.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INVA Today?
No stock-specific AI insight has been generated for INVA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.52$25.14
$22.52
Fundamentals
Market Cap$1.7B
P/E Ratio6.8
EPS$3.30
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.7%
Debt / Equity—
Trading
Volume618K
Avg Volume (10D)—
Shares Outstanding74.1M
INVA News
20 articles- Innoviva (INVA) Tops Q1 Earnings EstimatesYahoo Finance·May 7, 2026
- Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressYahoo Finance·May 6, 2026
- 3 Bargain-Cheap Small Caps Worth a Second LookInvesting.com·Apr 9, 2026
- Beacon Biosignals Upsizes Series B Financing to Over $97 MillionYahoo Finance·Apr 6, 2026
- Analysts See This Pharma Stock Surging 60%; Eyes Fresh EntryYahoo Finance·Apr 2, 2026
- Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price GainsYahoo Finance·Mar 24, 2026
- Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-UpYahoo Finance·Mar 23, 2026
- Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround PotentialMotley Fool·Mar 23, 2026
- Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark ReportYahoo Finance·Mar 10, 2026
- Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s WhyYahoo Finance·Mar 1, 2026
- Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price RunYahoo Finance·Mar 1, 2026
- Innoviva, Inc. (INVA): A Bull Case TheoryYahoo Finance·Feb 28, 2026
- Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer ConferenceMarketbeat·Feb 28, 2026
- Celldex Therapeutics Stock Earns 88 RS RatingYahoo Finance·Feb 26, 2026
- Nurix Therapeutics Stock Sees RS Rating Jump To 82Yahoo Finance·Feb 26, 2026
- Innoviva: Q4 Earnings SnapshotYahoo Finance·Feb 25, 2026
- Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company ProgressYahoo Finance·Feb 25, 2026
- CRISPR Therapeutics Stock Sees RS Rating Rise To 73Yahoo Finance·Feb 24, 2026
- Xenon Pharmaceuticals Stock Scores RS Rating UpgradeYahoo Finance·Feb 24, 2026
- AtaiBeckley names Michael Faerm as finance chiefProactive Investors·Feb 19, 2026
All 20 articles loaded
Price Data
Open$23.03
Previous Close$22.65
Day High$23.29
Day Low$22.64
52 Week High$25.14
52 Week Low$16.52
52-Week Range
$16.52$25.14
$22.52
Fundamentals
Market Cap$1.7B
P/E Ratio6.8
EPS$3.30
Dividend Yield—
Dividend / Share—
ROE0.3%
Profit Margin0.7%
Debt / Equity—
Trading
Volume618K
Avg Volume (10D)—
Shares Outstanding74.1M
About Innoviva Inc
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—